CytomX Therapeutics Inc [NASDAQ: CTMX] traded at a high on 2025-09-24, posting a 14.22 gain after which it closed the day’ session at $2.41.
The results of the trading session contributed to over 13306440 shares changing hands. Over the past one week, the price volatility of CytomX Therapeutics Inc stands at 7.52% while the volatility over the past one month is 6.34%.
The market cap for CTMX stock reached $397.44 million, with 164.91 million shares outstanding and 122.73 million shares in the current float. Compared to the average trading volume of 2.59M shares, CTMX reached a trading volume of 13306440 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CytomX Therapeutics Inc [CTMX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTMX shares is $5.79 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTMX stock is a recommendation set at 1.38. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for CytomX Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 22, 2025. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on September 17, 2025, representing the official price target for CytomX Therapeutics Inc stock. Previously, the target price had yet another raise to $7, while Oppenheimer analysts kept a Outperform rating on CTMX stock.
The Price to Book ratio for the last quarter was 3.31, with the Price to Cash per share for the same quarter was set at 0.96.
How has CTMX stock performed recently?
CytomX Therapeutics Inc [CTMX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 24.87. With this latest performance, CTMX shares gained by 20.50% in over the last four-week period, additionally plugging by 291.81% over the last 6 months – not to mention a rise of 133.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTMX stock in for the last two-week period is set at 64.29, with the RSI for the last a single of trading hit 0.15, and the three-weeks RSI is set at 0.15 for CytomX Therapeutics Inc [CTMX]. The present Moving Average for the last 50 days of trading for this stock 2.15, while it was recorded at 2.12 for the last single week of trading, and 1.49 for the last 200 days.
CytomX Therapeutics Inc [CTMX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and CytomX Therapeutics Inc [CTMX] shares currently have an operating margin of 30.56% and a Gross Margin at 98.88%. CytomX Therapeutics Inc’s Net Margin is presently recorded at 34.01%.
CytomX Therapeutics Inc (CTMX) Capital Structure & Debt Analysis
According to recent financial data for CytomX Therapeutics Inc. ( CTMX), the Return on Equity (ROE) stands at 108.21%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 28.71%, reflecting the company’s efficiency in generating profits from its assets. Additionally, CytomX Therapeutics Inc’s Return on Invested Capital (ROIC) is 39.54%, showcasing its effectiveness in deploying capital for earnings.
CytomX Therapeutics Inc (CTMX) Efficiency & Liquidity Metrics
Based on CytomX Therapeutics Inc’s (CTMX) latest financial statements, the Debt-to-Equity Ratio is 0.06%, indicating its reliance on debt financing relative to shareholder equity.
CytomX Therapeutics Inc (CTMX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, CytomX Therapeutics Inc. (CTMX) effectively leverages its workforce, generating an average of $396528.93 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.20% and a Quick Ratio of 4.20%, indicating strong ability to cover short-term liabilities.
Earnings analysis for CytomX Therapeutics Inc [CTMX]
With the latest financial reports released by the company, CytomX Therapeutics Inc posted 0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.2. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CTMX.
Insider trade positions for CytomX Therapeutics Inc [CTMX]
There are presently around $89.74%, or 90.46%% of CTMX stock, in the hands of institutional investors. The top three institutional holders of CTMX stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 7.79 million shares, which is approximately 9.1799%. JANUS HENDERSON GROUP PLC, holding 6.3 million shares of the stock with an approximate value of $$7.72 million in CTMX stocks shares; and JANUS HENDERSON GROUP PLC, currently with $$6.38 million in CTMX stock with ownership which is approximately 6.1598%.
